ECMO Braile Biomédica® in COVID-19 Patients

Braile Biomedica Ind. Com. e Repr. Ltda.30 enrolled

Overview

Retrospective data collection to evaluate the gas transfer capacity of the Braile Biomédica® OxyPrime® ECMO BRCoating® Membrane Oxygenator in COVID-19 patients during the pandemic.

Multicenter, retrospective, non-comparative, non-randomized study to assess the clinical performance of the OxyPrime® ECMO BRCoating® Membrane Oxygenator in adult patients with COVID-19

Study Type

OBSERVATIONAL

Enrollment

Conditions

COVID-19

Interventions

Patients underwent cardiorespiratory supportDEVICE

Patients underwent cardiorespiratory support using the Oxyprime® ECMO Braile Biomédica® Membrane Oxygenator

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients ≥ 18 years old, with a previous diagnosis of COVID-19, who were placed on ECMO using the Oxyprime® ECMO Braile Biomédica® Membrane Oxygenator, from March 2020 to July 2022, following the Instructions for Use (IFU) of the products. Exclusion Criteria: * Patients without a diagnosis of COVID-19

Locations (1)

Hospital Brasília

Lago Sul, Brasília - DF, Brazil

RECRUITING

Outcomes

Primary Outcomes

The effectiveness of the oxygenator in ensuring adequate gas exchange

To ensure adequate oxygenation (post-membrane pO2 \> 150 mmHg during the first week of use) and CO2 elimination (post-membrane pCO2 \< 40 mmHg or pre-membrane pCO2 - post-membrane pCO2 \> 10 mmHg)

Time frame: during the first week of use

The effectiveness of the set in ensuring adequate flow to the patient

Nominal flow calculated according to weight or body surface area (50 to 80 mL/Kg or 2.4 L/min of body surface area